Biogen Inc. (BIIB)

Market Cap	26.81B
Revenue (ttm)	10.07B
Net Income (ttm)	1.61B
Shares Out	146.70M
EPS (ttm)	10.97
PE Ratio	16.66
Forward PE	14.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	304,050
Open	181.96
Previous Close	181.98
Day's Range	181.10 - 183.03
52-Week Range	110.04 - 185.17
Beta	0.13
Analysts	Buy
Price Target	176.48 (-3.43%)
Earnings Date	Oct 30, 2025

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Sep 16, 1991
• Employees: 7,605
• Stock Exchange: NASDAQ
• Ticker Symbol: BIIB
• Website: https://www.biogen.com

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Analyst Summary

According to 23 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price target is $176.48, which is a decrease of -3.43% from the latest price.

Price Target

$176.48

(-3.43% downside)

Analyst Consensus: Buy